Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2004

01-03-2004 | Article

Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients

Authors: R. Colodner, W. Rock, B. Chazan, N. Keller, N. Guy, W. Sakran, R. Raz

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2004

Login to get access

Abstract

Although the risk factors for acquiring infection by extended-spectrum beta-lactamase (ESBL)-producing bacteria have been investigated in hospitalized patients, such risk factors have not been defined in the community setting. In this study, clinical data from a total of 311 nonhospitalized patients with community-acquired urinary tract infection (128 with ESBL-positive strains and 183 with ESBL-negative strains) were obtained. According to a multivariate analysis, the following were identified as independent risk factors: previous hospitalization in the past 3 months (OR=8.95, 95%CI, 3.77–21.25), antibiotic treatment in the past 3 months (OR=3.23, 95%CI, 1.76–5.91), age over 60 years (OR=2.65, 95%CI, 1.45–4.83), diabetes (OR=2.57, 95%CI, 1.20–5.51), male gender (OR=2.47, 95%CI, 1.22–5.01), Klebsiella pneumoniae infection (OR=2.31, 95%CI, 1.17–4.54), previous use of third-generation cephalosporins (P=0.014, OR=15.8, 95%CI, 1.7–143), previous use of second-generation cephalosporins (P<0.0001, OR=10.1, 95%CI, 4.2–24), previous use of quinolones (P=0.001, OR=4.1, 95%CI, 1.8–9.0), and previous use of penicillin (P=0.003, OR=4.0, 95%CI, 1.6–9.0).
Literature
1.
go back to reference Bush K (1996) Is it important to identify extended-spectrum beta-lactamase-producing isolates? Eur J Clin Microb Infect Dis 15:361–364 Bush K (1996) Is it important to identify extended-spectrum beta-lactamase-producing isolates? Eur J Clin Microb Infect Dis 15:361–364
2.
go back to reference Shah PW, Stille W (1983) Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third-generation cephalosporins. J Antimicrob Chemother 11:597–598PubMed Shah PW, Stille W (1983) Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third-generation cephalosporins. J Antimicrob Chemother 11:597–598PubMed
3.
go back to reference Jarlier V, Nicolas MH, Fournier G, Philippon A (1988) Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern. Rev Infect Dis 10:867–878PubMed Jarlier V, Nicolas MH, Fournier G, Philippon A (1988) Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern. Rev Infect Dis 10:867–878PubMed
4.
go back to reference Jacoby GA, Medeiros AA, O’Brien TF, Pinto ME, Jiang H (1988) Broad-spectrum, transmissible beta-lactamases. N Engl J Med 319:723–724PubMed Jacoby GA, Medeiros AA, O’Brien TF, Pinto ME, Jiang H (1988) Broad-spectrum, transmissible beta-lactamases. N Engl J Med 319:723–724PubMed
5.
go back to reference Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K (1989) Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemoter 33:1451–1456 Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K (1989) Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemoter 33:1451–1456
6.
go back to reference Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, Mohapatra S, Trenholme GM, Klugman KP, McCormack JG, Yu VL (2000) Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 30:473–478CrossRefPubMed Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, Mohapatra S, Trenholme GM, Klugman KP, McCormack JG, Yu VL (2000) Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 30:473–478CrossRefPubMed
7.
go back to reference Rice LB (1999) Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antibiotics. Pharmacotheropy 19 (8 Pt 2):120S–128S Rice LB (1999) Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antibiotics. Pharmacotheropy 19 (8 Pt 2):120S–128S
8.
go back to reference Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J, Garrigosa F, Ariza J, Gudiol F (1997) Risk factors for faecal carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase in the intensive care unit. J Hosp Infect 35:9–16PubMed Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J, Garrigosa F, Ariza J, Gudiol F (1997) Risk factors for faecal carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase in the intensive care unit. J Hosp Infect 35:9–16PubMed
9.
go back to reference Ho PL, Chan WM, Tsang KW, Wong SS, Young K (2002) Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy 22:14–20PubMed Ho PL, Chan WM, Tsang KW, Wong SS, Young K (2002) Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy 22:14–20PubMed
10.
go back to reference Mangeney N, Niel P, Paul G, Faubert E, Hue S, Dupeyron C, Louarn F, Leluan G (2000) A 5-year epidemiological study of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a medium- and long-stay neurological unit. J Appl Microbiol 88:504–511CrossRefPubMed Mangeney N, Niel P, Paul G, Faubert E, Hue S, Dupeyron C, Louarn F, Leluan G (2000) A 5-year epidemiological study of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a medium- and long-stay neurological unit. J Appl Microbiol 88:504–511CrossRefPubMed
11.
go back to reference Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB (1999) Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chem 44:359–365CrossRef Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB (1999) Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chem 44:359–365CrossRef
12.
go back to reference Colodner R, Keness Y, Chazan B, Raz R (2001) Antimicrobial susceptibility of community-acquired uropathogens in northern Israel. Int J Antimicrob Agents 18:189–192 Colodner R, Keness Y, Chazan B, Raz R (2001) Antimicrobial susceptibility of community-acquired uropathogens in northern Israel. Int J Antimicrob Agents 18:189–192
13.
go back to reference Clarridge JE, Johnson JR, Pezzlo, AM (1998) Laboratory diagnosis of urinary tract infections. Cumitech 2B. American Society for Microbiology Press, Washington DC Clarridge JE, Johnson JR, Pezzlo, AM (1998) Laboratory diagnosis of urinary tract infections. Cumitech 2B. American Society for Microbiology Press, Washington DC
14.
go back to reference National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Document M100-S12. NCCLS, Wayne, PA, p 39 National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Document M100-S12. NCCLS, Wayne, PA, p 39
15.
go back to reference Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F (2002) Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monit 8:44–47 Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F (2002) Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monit 8:44–47
16.
go back to reference Raz R, Okev N, Kennes Y, Gilboa A, Lavi I, Bisharat N (2000) Demographic characteristics of patients with community-acquired bacteriuria and susceptibility of urinary pathogens to antimicrobials in northern Israel. Isr Med Assoc J 2:426–429PubMed Raz R, Okev N, Kennes Y, Gilboa A, Lavi I, Bisharat N (2000) Demographic characteristics of patients with community-acquired bacteriuria and susceptibility of urinary pathogens to antimicrobials in northern Israel. Isr Med Assoc J 2:426–429PubMed
17.
go back to reference Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E (2002) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 23:254–260PubMed Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E (2002) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 23:254–260PubMed
18.
go back to reference Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA (1999) Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517–523CrossRefPubMed Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA (1999) Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517–523CrossRefPubMed
19.
go back to reference Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ (1993) Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 119:353–358PubMed Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ (1993) Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 119:353–358PubMed
Metadata
Title
Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients
Authors
R. Colodner
W. Rock
B. Chazan
N. Keller
N. Guy
W. Sakran
R. Raz
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1084-2

Other articles of this Issue 3/2004

European Journal of Clinical Microbiology & Infectious Diseases 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine